Medical Condition News

RSS

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

20 Oct 2009

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.

20 Oct 2009

Human neural stem cells protect cone photoreceptors: StemCells preclinical data

StemCells, Inc. announced today new preclinical data showing that its human neural stem cells protect cone photoreceptors (cones) in the eye from progressive degeneration and preserve visual function long term.

20 Oct 2009

Report: National investment on childhood and adolescent cancer research

The first-ever detailed examination of a country's investment in research on childhood and adolescent cancers was released today by the Canadian Cancer Research Alliance (CCRA) and the Canadian Partnership Against Cancer (the Partnership).

20 Oct 2009

Researchers use biotechnological tools to find a cure for Alzheimer's disease

No one has yet found a cure or a way to prevent people from developing Alzheimer's disease. Researchers from the Swedish University of Agricultural Sciences, among others, are breaking new ground in biotechnology to find new tools that can help provide new solutions.

20 Oct 2009

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Most Canadians living with CKD have likely never spoken with their physicians about calcium and the serious health risks associated with its overuse. This is why Improving Patient Advocacy in Chronic Kidney Disease (ImPACKD), a group of CKD patients and caregivers committed to raising awareness about the risks of calcium overuse, is starting the conversation about the importance of knowing the limits and keeping them in check.

20 Oct 2009

Women without HOXA13 gene mutation need not be subjected to X-rays

Hugh S. Taylor, M.D., professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, and colleagues have found that women without mutations of the HOXA13 gene do not need to be subjected to x-rays and other tests for a rare condition called hand-foot genital syndrome. The research is presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21.

20 Oct 2009

DCPR classification provides diagnostic criteria to evaluate psychosomatic syndromes

An investigation headed by Piero Porcelli (Bari, Italy) has yielded new insights as to what affects how a patient perceives his/her illness. It is published in the current issue of Psychotherapy and Psychosomatics.

20 Oct 2009

Individuals and governments around the globe should join the fight against osteoporosis: IOF

Speaking in Rome, Italy today on the occasion of World Osteoporosis Day, International Osteoporosis Foundation (IOF) CEO Patrice McKenney called for individuals and governments around the globe to join the fight against osteoporosis. "Osteoporosis is a common but devastating disease which we cannot afford to ignore. Immediate measures must be taken to reduce the burden of osteoporotic fractures through prevention, early recognition of fracture risk, and appropriate proven treatment for those in need," she urged.

20 Oct 2009

Presentation highlights the administration of autologous stem cells for treating spinal cord injury

DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience's 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL.

20 Oct 2009

NCCN Guidelines for Acute Myeloid Leukemia updated

The National Comprehensive Cancer Network (NCCN) recently made updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Acute Myeloid Leukemia, a cancer that starts inside the bone marrow and the most common acute leukemia affecting adults.

20 Oct 2009

IntegraMed America expands its Attain IVF treatment financing offerings

IntegraMed America, Inc., the nation’s leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced that it has expanded its Attain™ IVF (In Vitro Fertilization) family of treatment financing offerings to include the Attain IVF Multi-Cycle Program.

20 Oct 2009

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

PhRMA calls for appropriate incentives for continued biotechnology innovation

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding appropriate incentives for continued biotechnology innovation:

20 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

Repligen completes patient treatment in its Phase 3 RG1068 clinical trial

Repligen Corporation reported today that it has completed patient treatment in its Phase 3 clinical trial of RG1068, synthetic human secretin, in magnetic resonance imaging (MRI) of the pancreas. The study is designed to assess the sensitivity and specificity of RG1068 in conjunction with MRI for the detection of pancreatic duct abnormalities compared to MRI alone.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Study explores the efficacy of antidepressant drugs for patients with severe depression and medical disorder

This study demonstrates that over 6 weeks of treatment, patients with melancholic depression and medical comorbidity (MC) (specifically cardiovascular or endocrinological MC) had poorer treatment response and a worse functional outcome as opposed to their counterparts without MC. Interestingly, these effects were not related to various antidepressant treatment regimens.

20 Oct 2009

Day care center integrates diabetes care for children into its routine as part of ADA settlement

Pine Hills Kiddie Garden of Fort Wayne, Ind., will take necessary steps to ensure that a child's diabetes care is integrated into the usual routine of its day care center and programs as part of a settlement to resolve allegations that it discriminated on the basis of disability, the Justice Department announced today.

20 Oct 2009

Medical Condition News

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

Targacept presents data from Phase 2b clinical trial of TC-5214

Human neural stem cells protect cone photoreceptors: StemCells preclinical data

Report: National investment on childhood and adolescent cancer research

Researchers use biotechnological tools to find a cure for Alzheimer's disease

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Women without HOXA13 gene mutation need not be subjected to X-rays

DCPR classification provides diagnostic criteria to evaluate psychosomatic syndromes

Individuals and governments around the globe should join the fight against osteoporosis: IOF

Presentation highlights the administration of autologous stem cells for treating spinal cord injury

NCCN Guidelines for Acute Myeloid Leukemia updated

IntegraMed America expands its Attain IVF treatment financing offerings

Two high blood pressure medicines effective in treating stable ischemic heart disease

PhRMA calls for appropriate incentives for continued biotechnology innovation

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Repligen completes patient treatment in its Phase 3 RG1068 clinical trial

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Study explores the efficacy of antidepressant drugs for patients with severe depression and medical disorder

Day care center integrates diabetes care for children into its routine as part of ADA settlement

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News